NervGen gene therapy slashes functional deficits in spinal cord injury trial
NervGen Pharma (NYSE:NGEN) reported positive results from an independent, blinded biomechanical gait analysis of its Phase 1b/2a CONNECT SCI study, demonstrating that its lead candidate, NVG-291, achieved statistically significant improvements in walking quality among chronic spinal cord injury patients.










